Page last updated: 2024-11-04

risedronic acid and Hyperparathyroidism, Secondary

risedronic acid has been researched along with Hyperparathyroidism, Secondary in 2 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Hyperparathyroidism, Secondary: Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.

Research Excerpts

ExcerptRelevanceReference
"Treatment with menatetrenone, risedronate or regular sunlight exposure are safe and effective in increasing bone mass and reducing the risk of hip fracture in patients with AD."2.46[Dementia and fracture]. ( Sato, Y, 2010)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sato, Y1
Torregrosa, JV1
DurĂ¡n, CE1
Barros, X1
Blasco, M1
Arias, M1
Cases, A1
Campistol, JM1

Reviews

1 review available for risedronic acid and Hyperparathyroidism, Secondary

ArticleYear
[Dementia and fracture].
    Clinical calcium, 2010, Volume: 20, Issue:9

    Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism

2010

Trials

1 trial available for risedronic acid and Hyperparathyroidism, Secondary

ArticleYear
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, May-14, Volume: 32, Issue:3

    Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphon

2012